Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells - Wikidata - awgldk - TriplyDB

Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells

Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells

http://www.wikidata.org/entity/Q34022393

about

CRISPR/Cas9 and cancer targets: future possibilities and present challenges Epigenome engineering in cancer: fairytale or a realistic path to the clinic?Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells Genome editing and the next generation of antiviral therapy.The CRISPR/Cas9 genome editing methodology as a weapon against human viruses CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9 CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.CRISPR-Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies.CrisprGE: a central hub of CRISPR/Cas-based genome editing.Therapeutic gene editing: delivery and regulatory perspectives Type II CRISPR/Cas9 approach in the oncological therapy.ge-CRISPR - An integrated pipeline for the prediction and analysis of sgRNAs genome editing efficiency for CRISPR/Cas system.The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System.Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse.Therapeutic vaccines for high-risk HPV-associated diseases.CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells.Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy

P2860

Q26769907-270BEAE8-1EA1-4539-BFC0-C14AC2895435 Q26861350-50FF7833-111D-445D-913A-9DD29D80ECF3 Q28087526-90A9226A-C03F-4E29-A170-2A5E76676EB7 Q33905878-BBE0794B-327B-4B04-B509-4A35DFC24449 Q34529971-009A9194-CE21-4117-8B0F-0123F80A7BF1 Q35654689-F629249D-E1F1-4A4A-A883-C4326A3EFAB4 Q35770584-8AA9285D-5A93-4737-90D9-F4A55B21F7EE Q36216276-3C240EF6-A3E9-4EF1-8968-C340EE70E867 Q36494284-9D301F0B-A421-42E1-9EA8-F6C0DE5119E3 Q37411994-C3E6C90F-6B77-463E-827A-4E5DBA3644DA Q37559174-E7E33075-E467-4BAF-8ED6-1DAAB93325A6 Q38516454-6670565F-E8F9-46F9-9E7A-4B26D2EBC531 Q38859113-1416E8E3-3987-4774-8B8C-AD2FF204EA72 Q39230418-D8B88D5D-B589-4597-A70B-2D36B8BD0C20 Q39376221-C5893970-36D8-448A-8F7F-5F02B3F445AE Q39434768-23B1D5E8-28BD-4DC5-B157-C70C82589076 Q41035560-541360DD-15BD-42EE-BA7D-F357AC5DBBF2 Q41930897-613A7B92-82FA-4521-A775-5E3446570357 Q46208205-8AFF057C-0373-49EF-8F3A-F32473E18CE5 Q47255618-70B185A8-48D1-46BC-A028-74CD6E311431 Q47275614-8CC03387-6607-453F-B1CB-F50ADE2543C9 Q57039753-AEFDE1A1-1797-4AF0-B919-B3B1A64D5D30

P2860

Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells

http://www.wikidata.org/entity/Q34022393

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@ast

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@en

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@nl

type

label

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@ast

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@en

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@nl

prefLabel

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@ast

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@en

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@nl

P1433

Q34022393-9C02E52A-158A-4CD3-8EF7-CA2B339C0A85

P1476

Q34022393-57065C8C-C199-4A7B-83EE-FDAA518F52D2

P2093

Q34022393-07807934-E6BC-451A-AACB-2AAC94D0C0FD

Q34022393-18C7F4AB-A60D-4636-8B72-32C91C397A24

Q34022393-2341601D-4099-46E1-A6A4-6000DFC67602

Q34022393-51A3792D-B746-4E0A-8803-718A8579444C

Q34022393-709660E2-DC0C-42F9-9A93-08CE0D0B3502

Q34022393-71B0D8F1-40F2-4EED-9CBF-480B28CD14FD

Q34022393-8369330B-97CF-4249-8523-0E0CC9CBA9D1

Q34022393-9D35E211-B49F-43CE-BC70-A8AB841216CE

Q34022393-AC8AD9D7-23CF-411F-93B1-FA9BEBC30343

Q34022393-B99AE0A7-DE05-43A8-9CF0-84BCB494356F

P2860

Q34022393-17AA3539-BBD2-41BA-A37A-101899B534A4

Q34022393-18FDD0D7-CFF5-4AB4-9728-755466101C13

Q34022393-398A6AD3-9202-450A-A00D-2236242ED27B

Q34022393-3E92B17A-EB46-446D-A1EA-A20049862FDE

Q34022393-4835B263-A903-4152-A13A-BAB2E1735AB9

Q34022393-4A821BA1-FCFD-4FF4-B15F-01A4F11ABB0F

Q34022393-550E9179-2C40-4F40-93E5-E9EF83D33050

Q34022393-667766B8-1996-409A-8526-93A02E7F667E

Q34022393-A2F5866A-5ED2-446C-B5F3-D5D6BF22D9C0

Q34022393-BEBED3CF-16B5-47F0-90DA-009579C54BDD

P304

Q34022393-BF0D6ECE-2A40-4F23-A7F9-204D5B115E36

P31

Q34022393-C3E3190C-2F9B-470D-B7CC-01A2FE8A051B

P356

Q34022393-1E0DBC6C-F299-4EC2-B99C-27E53E3C6368

P407

Q34022393-CDB01F2C-808A-4CBA-9BA2-5CF76EC1C7BC

P478

Q34022393-17603640-C8D7-4B10-B047-404E316D233B

P50

Q34022393-19C52F1F-2FC3-48B2-8948-4B7C7C48C2F9

P577

Q34022393-B8D70200-0C4C-4254-A829-639BD7B2A927

P5875

Q34022393-D4E85AA5-A403-4C3D-B319-2B0D409D2358

P698

Q34022393-710F2BFA-0F2E-42CA-9A53-7DC3BBC15BAD

P921

Q34022393-76DBE52C-9DC9-4F4D-B57F-201D27104F6E

P932

Q34022393-D38F489F-C82C-4BBA-91D4-8C5BB7646D47

P356

P1433

BioMed Research International

P1476

Disruption of HPV16-E7 by CRIS ...... ve human cervical cancer cells

@en

P2093

Changlin Zhang

http://www.w3.org/2001/XMLSchema#string

Da Zhu

http://www.w3.org/2001/XMLSchema#string

Dan He

http://www.w3.org/2001/XMLSchema#string

Hui Shen

http://www.w3.org/2001/XMLSchema#string

Hui Wang

http://www.w3.org/2001/XMLSchema#string

Kezhen Li

http://www.w3.org/2001/XMLSchema#string

Lan Yu

http://www.w3.org/2001/XMLSchema#string

Liming Wang

http://www.w3.org/2001/XMLSchema#string

Ling Xi

http://www.w3.org/2001/XMLSchema#string

Wencheng Ding

http://www.w3.org/2001/XMLSchema#string

P2860

CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes

RNA-guided human genome engineering via Cas9

Efficient genome editing in zebrafish using a CRISPR-Cas system

Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly

The promises and pitfalls of RNA-interference-based therapeutics

Pathways of DNA double-strand break repair during the mammalian cell cycle

Papillomaviruses and cancer: from basic studies to clinical application

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.

P304

612823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/612823

http://www.w3.org/2001/XMLSchema#string

P407

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264866664

http://www.w3.org/2001/XMLSchema#string

P698

25136604

http://www.w3.org/2001/XMLSchema#string

P921

P932

4127252

http://www.w3.org/2001/XMLSchema#string